← Leaderboards
Evan B. Stubbs
Edward Hines Jr Va Hospital
$455,775
Attributed
$455,775
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $183.8K · FY2008–24$200K$150K$100K$50K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$455,775 · 2
VA$0 · 5
By mechanism
R21$336,875 · 1
R03$118,900 · 1
I01$0 · 2
I21$0 · 3
Top collaborators
- Morris Fisher4 shared
Most similar at Edward Hines Jr Va Hospital
Same institution · by research overlap
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectPalliativePrevalenceVeteransNeuropathySocioeconomicsAttenuatedMediatingImmunohistochemistryBlindnessResponsePeripheral Nervous System DiseasesReportingPeripheral NervesCaringInhibitor/AntagonistDoseFunctional DisorderCytokineQuality Of LifeIn VivoEtiologyEconomic BurdenAmerican
Grant awards (20)
Translamina Cribrosa Pressure Gradient Model of Normal Tension Glaucoma$0
I21 · FY2024 · VA · contact PI
Translamina Cribrosa Pressure Gradient Model of Normal Tension Glaucoma$0
I21 · FY2023 · VA · contact PI
Translamina Cribrosa Pressure Gradient Model of Normal Tension Glaucoma$0
I21 · FY2022 · VA · contact PI
Mitochondrial-Targeted Antioxidant-Encapsulating Nanoparticles as a Promising Therapeutic Strategy in Regulating Outflow Resistance$0
I01 · FY2021 · VA · contact PI
Mitochondrial-Targeted Antioxidant-Encapsulating Nanoparticles as a Promising Therapeutic Strategy in Regulating Outflow Resistance$0
I01 · FY2020 · VA · contact PI
Mitochondrial-Targeted Antioxidant-Encapsulating Nanoparticles as a Promising Therapeutic Strategy in Regulating Outflow Resistance$0
I01 · FY2019 · VA · contact PI
Mitochondrial-Targeted Antioxidant-Encapsulating Nanoparticles as a Promising Therapeutic Strategy in Regulating Outflow Resistance$0
I01 · FY2018 · VA · contact PI
Rho GTPase siRNA as a Therapeutic Strategy in Regulating Outflow Resistance$0
I21 · FY2017 · VA · contact PI
Rho GTPase siRNA as a Therapeutic Strategy in Regulating Outflow Resistance$0
I21 · FY2016 · VA · contact PI
Rho GTPase siRNA as a Therapeutic Strategy in Experimental Autoimmune Neuritis$0
I21 · FY2016 · VA · contact PI
Mechanistic Role of Monomeric GTPases in Experimental Autoimmune Neuritis$183,750
R21 · FY2015 · NS · contact PI
Rho GTPase siRNA as a Therapeutic Strategy in Experimental Autoimmune Neuritis$0
I21 · FY2015 · VA · contact PI
Rho GTPase siRNA as a Therapeutic Strategy in Experimental Autoimmune Neuritis$0
I21 · FY2015 · VA · contact PI
Mechanistic Role of Monomeric GTPases in Experimental Autoimmune Neuritis$153,125
R21 · FY2014 · NS · contact PI
Exercise-Facilitated NeuroRehabilitation in Diabetic Neuropathy$0
I01 · FY2014 · VA · contact PI
Exercise-Facilitated NeuroRehabilitation in Diabetic Neuropathy$0
I01 · FY2014 · VA · contact PI
Exercise-Facilitated NeuroRehabilitation in Diabetic Neuropathy$0
I01 · FY2014 · VA · contact PI
Protection against acute inflammatory demyelinating peripheral nerve disease$59,450
R03 · FY2009 · NS · contact PI
Exercise-Facilitated NeuroRehabilitation in Diabetic Neuropathy$0
I01 · FY2009 · VA · contact PI
Protection against acute inflammatory demyelinating peripheral nerve disease$59,450
R03 · FY2008 · NS · contact PI